BioInvent International AB (publ) (STO:BINV)

Sweden flag Sweden · Delayed Price · Currency is SEK
28.85
-0.20 (-0.69%)
At close: Dec 5, 2025
-34.28%
Market Cap 1.90B
Revenue (ttm) 244.85M
Net Income (ttm) -323.94M
Shares Out 65.80M
EPS (ttm) -4.93
PE Ratio n/a
Forward PE 2.96
Dividend n/a
Ex-Dividend Date n/a
Volume 58,495
Average Volume 86,910
Open 29.40
Previous Close 29.05
Day's Range 28.30 - 29.40
52-Week Range 22.70 - 44.35
Beta -0.06
RSI 48.72
Earnings Date Feb 26, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 114
Stock Exchange Nasdaq Stockholm
Ticker Symbol BINV
Full Company Profile

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.

Financial Statements

News

BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ...

BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst Financial Challenges

5 weeks ago - GuruFocus

Q3 2025 BioInvent International AB Earnings Call Transcript

Q3 2025 BioInvent International AB Earnings Call Transcript

5 weeks ago - GuruFocus

Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, B...

1 year ago - Benzinga